沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09996 沛嘉医疗-B

已收盘 12-15 16:08:35

6.100

-0.100

-1.61%

最高6.340	最低6.020	成交量80.07万
今开6.320	昨收6.200	日振幅5.16%
总市值40.93亿	流通市值40.93亿	总股本6.71亿
成交额492.96万	换手率0.12%	流通股本6.71亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09996","market":"HK","secType":"STK","nameCN":"沛嘉医疗-B","latestPrice":6.1,"timestamp":1765786115007,"preClose":6.2,"halted":0,"volume":800650,"delay":0,"floatShares":671000000,"shares":671000000,"eps":-0.3740342456633229,"marketStatus":"已收盘","change":-0.1,"latestTime":"12-15 16:08:35","open":6.32,"high":6.34,"low":6.02,"amount":4929646,"amplitude":0.051613,"askPrice":6.11,"askSize":2000,"bidPrice":6.1,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":-0.3754886900472385,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":5,"adr":0,"listingDate":1589472000000,"exchange":"SEHK","adjPreClose":6.2,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"volumeRatio":0.542372,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09996/tweets","defaultTab":"tweets","newsList":[{"id":"2591906648","title":"科华生物最新公告：旗下公司产品获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2591906648","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591906648?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:00","pubTimestamp":1765796412,"startTime":"0","endTime":"0","summary":"科华生物(002022.SZ)公告称，公司控股子公司西安天隆及全资子公司西安科华分别收到国家药品监督管理局、陕西省药品监督管理局颁发的医疗器械注册证（体外诊断试剂）。产品包括人类CYP3A5基因多态性检测试剂盒、25-羟基维生素D检测试剂盒和环孢霉素、他克莫司和雷帕霉素检测试剂盒。这些新产品的注册证将丰富公司产品线，对业务发展有正面影响，但对未来营业收入的影响尚无法预测。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500025577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0046","BK0188","BK1574","BK1222","BK0239","002022","09996","159883","BK0028","BK1100","09997"],"gpt_icon":0},{"id":"2591617949","title":"九强生物（300406）披露取得医疗器械注册证书，12月15日股价下跌1.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591617949","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591617949?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:03","pubTimestamp":1765792994,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，九强生物报收于13.21元，较前一交易日下跌1.93%，最新总市值为77.45亿元。该股当日开盘13.3元，最高13.34元，最低13.16元，成交额达6124.7万元，换手率为1.09%。公司近日发布公告称，北京九强生物技术股份有限公司近日收到北京市药品监督管理局颁发的《医疗器械注册证》，产品为果糖胺测定试剂盒，注册证编号京械注准20252400983，注册类别Ⅱ类，有效期至2030年12月08日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500023716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK0012","BK0046","BK1574","BK1222","BK0077","BK0239","300406","09996","159883","BK0028","BK1100","09997"],"gpt_icon":0},{"id":"2591617519","title":"亚辉龙(688575.SH)子公司取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2591617519","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591617519?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:59","pubTimestamp":1765792774,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚辉龙(688575.SH)发布公告，公司全资子公司湖南亚辉龙生物科技有限公司于近日收到了由湖南省药品监督管理局签发的医疗器械注册证，产品名称：抗磷脂酰丝氨酸/凝血酶原IgM抗体测定试剂盒(化学发光法)、抗磷脂酰丝氨酸/凝血酶原IgG抗体测定试剂盒(化学发光法)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381617.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1222","BK0239","09997","09996","BK1583","688575","BK1574","159883","BK1100"],"gpt_icon":0},{"id":"2591612958","title":"透景生命(300642.SZ)子公司取得一项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612958","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591612958?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:45","pubTimestamp":1765791945,"startTime":"0","endTime":"0","summary":"智通财经APP讯，透景生命(300642.SZ)公告，公司控股子公司武汉康录生物技术股份有限公司近日取得国家药品监督管理局颁发的1项医疗器械注册证，产品名为：产前染色体数目检测试剂盒(荧光原位杂交法)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0042","300642","BK1583","BK0046","BK0239","BK1222","BK1100","09997","BK1574","09996","159883"],"gpt_icon":0},{"id":"2591614824","title":"东方海洋(002086.SZ)子公司取得一项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2591614824","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591614824?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:08","pubTimestamp":1765789706,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东方海洋(002086.SZ)公告，公司子公司质谱生物科技有限公司自主研发的甲氨蝶呤检测试剂(液相色谱-串联质谱法)于近日取得了山东省药品监督管理局的注册批准，获得医疗器械注册证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381566.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0213","BK1100","BK1574","BK0092","BK1583","159883","09996","BK1222","09997","002086","BK0046"],"gpt_icon":0},{"id":"2591261188","title":"九强生物获果糖胺测定试剂盒医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2591261188","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591261188?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:39","pubTimestamp":1765787954,"startTime":"0","endTime":"0","summary":"中访网数据  北京九强生物技术股份有限公司近日宣布，其“果糖胺测定试剂盒(NBT法)”已获得由北京市药品监督管理局颁发的医疗器械注册证(注册证编号：京械注准20252400983)。该注册证类别为Ⅱ类，有效期自批准之日起至2030年12月08日。该产品为雅培仪器封闭通道配套专用试剂，用于体外定量测定人血清中果糖胺的含量。公司表示，此次新产品的获批丰富了其在体外诊断生化细分领域的产品线，有助于提升核心竞争力及市场拓展能力。不过，公司也提示，该产品的实际销售情况将取决于未来的市场推广效果，目前尚无法预测其对未来业绩的具体影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251215/31866001.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1574","300406","09996","BK0012","BK0077","BK0239","BK1100","BK1222","BK1583","BK0028","BK0046","159883","09997"],"gpt_icon":0},{"id":"2591613910","title":"医疗器械行业周报","url":"https://stock-news.laohu8.com/highlight/detail?id=2591613910","media":"中信建投证券股...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591613910?lang=zh_cn&edition=full","pubTime":"2025-12-14 20:41","pubTimestamp":1765716103,"startTime":"0","endTime":"0","summary":"近期医疗器械板块迈瑞医疗、新产业、惠泰医疗等部分大市值龙头公司有所回调，估值调整后将迎来长线布局良机，建议持续关注行业景气度恢复趋势、新产品放量和海外业务进展。长期来看，医疗器械行业投资机会来自创新、出海和并购整合，板块的创新和国际化能力得到认可，估值正在重构。医疗器械板块拐点来临，短期来看，Q4和26年业绩改善个股存在业绩估值修复机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214204147a6a13a70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214204147a6a13a70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09997","09996","BK1100","BK1222","BK1583","BK1574"],"gpt_icon":0},{"id":"2591230650","title":"国内AR治疗迎“领跑”时刻，创新器械TaurusTrio获批改写千万患者命运","url":"https://stock-news.laohu8.com/highlight/detail?id=2591230650","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591230650?lang=zh_cn&edition=full","pubTime":"2025-12-14 09:02","pubTimestamp":1765674120,"startTime":"0","endTime":"0","summary":"2025年12月12日，沛嘉医疗旗下TaurusTrio经导管主动脉瓣系统获国家药监局上市批准，这是国内首款获批的一体化定位键经股入路主动脉瓣反流专用介入治疗器械，早于美国FDA获批，标志我国在该领域实现从“跟跑”到“领跑”的跨越。我国单纯主动脉瓣反流患者数量是主动脉瓣狭窄患者的2倍，过去治疗艰难，TaurusTrio的获批打破困境，带来更优治疗选择，推动诊疗规范化。其核心是全球首创的一体式定位键设计，攻克器械锚定不稳难题，优势包括精准锚定、安全加码、兼顾长远。其国内注册临床ALTER-AR研究，自2023年7月启动，纳入116例中国症状性重度AR患者，结果验证了其安全性与有效性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214100522a69fc8da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214100522a69fc8da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09996","BK1574","BK1100","BK1583"],"gpt_icon":0},{"id":"2591638381","title":"Medline冲刺纳斯达克：募资超50亿美元 为医疗器械巨头 路演PPT曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2591638381","media":"雷递网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591638381?lang=zh_cn&edition=full","pubTime":"2025-12-13 09:25","pubTimestamp":1765589152,"startTime":"0","endTime":"0","summary":"全球医疗器械巨头Medline Industries（股票代码：“MDLN”）日前递交招股书，准备2025年12月17日在美国纳斯达克上市。Medline发行区间为26美元到30美元，发行1.79亿股，最高募资53.7亿美元。Medline估值可能超过500亿美元。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20251213/6390121474944189523400933.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20251213/6390121474944189523400933.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n32080/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["MNQmain","BK1222","USAW.SI","BK4007","SQQQ","QID","BK1574","TSYW.SI","TQQQ","09997","NVIW.SI","QLD","BK1147","09996","BK1100","PSQ","ARTL","PPT",".IXIC","BK1583","NQmain","USJW.SI","159632","03086","159883"],"gpt_icon":1},{"id":"2590502367","title":"苏州高新（600736）披露出售医疗器械产业公司47%股权被动形成对外担保议案，12月12日股价上涨2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590502367","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590502367?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:20","pubTimestamp":1765549226,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，苏州高新报收于5.95元，较前一交易日上涨2.06%，最新总市值为68.5亿元。该股当日开盘6.0元，最高6.11元，最低5.88元，成交额达2.83亿元，换手率为4.11%。近日，苏州高新发布2025年第三次临时股东会决议公告，公司于2025年12月12日召开第三次临时股东会，审议通过了关于出售医疗器械产业公司47%股权被动形成对外担保的议案。议案获出席会议股东所持表决权过半数通过，其中A股股东同意比例为98.2630%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200041611.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","09996","BK0028","BK0059","BK1100","BK1574","BK0178","BK0273","BK0075","600736","159883","BK1222","09997"],"gpt_icon":0},{"id":"1134872868","title":"沛嘉医疗-B获得NMPA批准，Taurustrio经导管主动脉瓣系统开创中国主动脉反流治疗新纪元","url":"https://stock-news.laohu8.com/highlight/detail?id=1134872868","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134872868?lang=zh_cn&edition=full","pubTime":"2025-12-12 20:31","pubTimestamp":1765542676,"startTime":"0","endTime":"0","summary":"沛嘉医疗-B获得NMPA批准，Taurustrio经导管主动脉瓣系统开创中国主动脉反流治疗新纪元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1583","09996","BK1574"],"gpt_icon":0},{"id":"2590571035","title":"沛嘉医疗-B12月12日主力净流入60.6万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590571035","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590571035?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:15","pubTimestamp":1765527344,"startTime":"0","endTime":"0","summary":"12月12日, 沛嘉医疗-B股价涨6.71%，报收6.20元，成交金额1156.3万元，换手率0.28%，振幅8.43%，量比1.45。沛嘉医疗-B今日主力资金净流入60.6万元，上一交易日主力净流出0万元。该股近5个交易日上涨11.73%，主力资金累计净流出7.6万元；近20日主力资金累计净流出409.5万元，其中净流出天数为10日。该股主力净额占比0.01%，港股市场排名386/2691。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512121625479539800c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512121625479539800c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09996","BK1100","BK1583","BK1574"],"gpt_icon":0},{"id":"2590615524","title":"港股沛嘉医疗-B涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590615524","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590615524?lang=zh_cn&edition=full","pubTime":"2025-12-12 11:48","pubTimestamp":1765511338,"startTime":"0","endTime":"0","summary":"每经AI快讯，沛嘉医疗-B(09996.HK)涨近7%，截至发稿，涨6.88%，报6.21港元，成交额748.78万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512123589984994.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512123589984994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1100","BK1574","09996","159891","BK1583"],"gpt_icon":0},{"id":"2590437599","title":"沛嘉医疗-B(09996)：TaurusTrio™经导管主动脉瓣系统的注册申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590437599","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590437599?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:17","pubTimestamp":1765444649,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B 发布公告，于2025年12月11日，本公司收到中华人民共和国国家药品监督管理局就TaurusTrio经导管主动脉瓣系统的注册申请发出的批准。TaurusTrio TAV系统由本公司基于自JenaValve Technology, Inc.获得的Trilogy经导管心脏瓣膜系统的独占许可开发及制造。本公司期待 TaurusTrio TAV系统于中国成功上市，预计将为患有重度AR的中国患者提供安全有效的治疗选择，从而满足一项重大未满足的临床需求。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1100","159891","BK1574","09996"],"gpt_icon":0},{"id":"2590546038","title":"每日卖空追踪 | 沛嘉医疗-B 12月11日卖空量成交6.1万股，卖空比例为6.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590546038","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590546038?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:30","pubTimestamp":1765441841,"startTime":"0","endTime":"0","summary":"沛嘉医疗-B北京时间12月11日，跌2.68%，卖空量成交6.1万股，较上一交易日减少45.05%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163832979c69fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163832979c69fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1100","BK1574","09996","BK1583"],"gpt_icon":0},{"id":"2590538063","title":"戴维医疗（300314）披露新产品获得医疗器械注册证，12月10日股价下跌0.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590538063","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590538063?lang=zh_cn&edition=full","pubTime":"2025-12-10 22:21","pubTimestamp":1765376466,"startTime":"0","endTime":"0","summary":"截至2025年12月10日收盘，戴维医疗报收于12.8元，较前一交易日下跌0.23%，最新总市值为36.86亿元。该股当日开盘12.83元，最高12.92元，最低12.71元，成交额达3002.2万元，换手率为1.63%。公司近日发布公告称，宁波戴维医疗器械股份有限公司的新产品电动手术台获得浙江省药品监督管理局颁发的《医疗器械注册证》。公告指出，该产品注册证的取得有助于丰富公司产品线，提升核心竞争力，对公司未来经营成果将产生积极影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000041938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09996","BK1100","BK1583","159883","BK0048","09997","BK0042","BK1222","BK1574","BK0046","BK0251","300314"],"gpt_icon":0},{"id":"2590867555","title":"迈克生物(300463.SZ)子公司收到一项医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2590867555","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590867555?lang=zh_cn&edition=full","pubTime":"2025-12-10 19:05","pubTimestamp":1765364714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈克生物(300463.SZ)公告，公司全资子公司迈克医疗电子有限公司于近日收到四川药品监督管理局颁发的《医疗器械注册证》，产品名称为：全自动细胞形态学分析仪。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","BK0028","09997","300463","09996","BK0046","BK0239","BK0012","BK1100","BK1574","BK1222","BK1583"],"gpt_icon":0},{"id":"2590867205","title":"中恒集团最新公告：控股孙公司获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2590867205","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590867205?lang=zh_cn&edition=full","pubTime":"2025-12-10 19:03","pubTimestamp":1765364590,"startTime":"0","endTime":"0","summary":"中恒集团(600252.SH)公告称，公司控股子公司重庆莱美药业之子公司海南莱美医疗器械有限公司近日收到海南省药品监督管理局颁发的两项《医疗器械注册证》，分别是医用电子内窥镜图像处理器和电子支气管镜，有效期均为2025年11月17日至2030年11月16日。该产品能直接观察患者图像，有利于临床使用对患者病症的判断及治疗。此次产品获证将进一步丰富公司医疗器械产品种类，满足市场多样化的需求，提升公司综合竞争力，对未来经营将产生积极影响。为证券之星据公开信息整理，由AI算法生成(网信算备310104345710301240019号)，不构成投资建议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20251210/31856961.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159883","BK1574","BK0012","600252","BK1100","BK1222","BK1583","BK0188","09996","BK0028","BK0015","09997","BK0077","BK0239"],"gpt_icon":0},{"id":"2590583796","title":"科华生物子公司全自动化学发光免疫分析仪获医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2590583796","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590583796?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:56","pubTimestamp":1765360604,"startTime":"0","endTime":"0","summary":"中访网数据  上海科华生物工程股份有限公司于2025年12月10日发布公告，其全资子公司科华(西安)生物工程有限公司近日获得陕西省药品监督管理局颁发的医疗器械注册证。获批产品为全自动化学发光免疫分析仪，注册证编号为陕械注准20252220247，有效期自2025年12月03日至2030年12月02日。该产品需与配套检测试剂共同使用，适用于临床对人体血清、血浆及其他体液样本中的被分析物进行定性或定量检测。公司表示，此次新产品获批将进一步丰富其产品线，并对公司业务发展产生正面影响，但当前尚无法预测该产品对未来营业收入的具体影响。投资者需关注相关投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251210/31856739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159883","BK0239","BK1583","BK0028","BK1222","09996","BK1100","BK0188","BK1574","09997","002022","BK0046"],"gpt_icon":0},{"id":"2590300881","title":"戴维医疗最新公告：公司新产品电动手术台获得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2590300881","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590300881?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:56","pubTimestamp":1765356987,"startTime":"0","endTime":"0","summary":"戴维医疗公告称，公司新产品电动手术台获得浙江省药品监督管理局颁发的《医疗器械注册证》。该产品采用电动液压控制方式，具有高承重和模块化设计特点，能够满足手术的多变性和患者的不同体位需求。新产品的取得将丰富公司产品线，提高核心竞争力，对未来经营成果产生积极影响。但目前无法预测对公司未来营业收入的具体影响，投资者需注意投资风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000026242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09997","BK0048","BK0046","BK0251","BK1583","BK1100","BK1574","300314","BK1222","159883","09996","BK0042"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.peijiamedical.com","stockEarnings":[{"period":"1week","weight":0.1191},{"period":"1month","weight":0.0333},{"period":"3month","weight":-0.1507},{"period":"6month","weight":-0.0432},{"period":"1year","weight":0.5385},{"period":"ytd","weight":0.5578}],"compareEarnings":[{"period":"1week","weight":-0.0042},{"period":"1month","weight":-0.0351},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0872},{"period":"1year","weight":0.2736},{"period":"ytd","weight":0.295}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"沛嘉医疗有限公司是一家主要提供介入手术医疗器械产品的投资控股公司。该公司主要运营两个业务分部，经导管瓣膜治疗业务分部和神经介入业务分部。经导管瓣膜治疗业务分部主要从事研发、制造及销售经导管瓣膜治疗医疗器械业务。神经介入业务分部主要从事研发、制造及销售神经介入手术医疗器械业务。该公司的产品包括TaurusOne、TaurusElite等商业化产品。该公司主要在中国境内开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.088172},{"month":2,"riseRate":0.6,"avgChangeRate":0.039503},{"month":3,"riseRate":0.4,"avgChangeRate":-0.110838},{"month":4,"riseRate":0.75,"avgChangeRate":0.044776},{"month":5,"riseRate":0.75,"avgChangeRate":-0.061692},{"month":6,"riseRate":0.666667,"avgChangeRate":0.07739},{"month":7,"riseRate":0.5,"avgChangeRate":0.047595},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.086603},{"month":9,"riseRate":0.333333,"avgChangeRate":0.014494},{"month":10,"riseRate":0.5,"avgChangeRate":-0.005393},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.027135},{"month":12,"riseRate":0.666667,"avgChangeRate":0.089605}],"exchange":"SEHK","name":"沛嘉医疗-B","nameEN":"PEIJIA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"沛嘉医疗-B,09996,沛嘉医疗-B股票,沛嘉医疗-B股票老虎,沛嘉医疗-B股票老虎国际,沛嘉医疗-B行情,沛嘉医疗-B股票行情,沛嘉医疗-B股价,沛嘉医疗-B股市,沛嘉医疗-B股票价格,沛嘉医疗-B股票交易,沛嘉医疗-B股票购买,沛嘉医疗-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"沛嘉医疗-B(09996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供沛嘉医疗-B(09996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}